Diversified health care giant Johnson & Johnson (NYSE:JNJ) saw continued fallout from a flurry of product recalls and concerns over its manufacturing controls as investors sent the stock towards its lows over the past year. The company also didn't bother to provide a full balance sheet or cash flow statement during its fourth quarter results, leaving investors to wonder about its finances and cash flows until it files full-year financial statements with the Securities and Exchange Commission.

IN PICTURES: 6 Simple Steps To $1 Million

Fourth Quarter Recap
The earnings press release did provide an income statement that detailed a 5.5% sales decline to $15.6 billion. Of the three operating divisions, the consumer unit was the notable laggard as sales fell 15% to account for 23% of sales. Product recalls of over-the-counter medicines hit the unit, as did a hip device recall in the DePuy medical device franchise, though total medical device sales eeked out 0.1% growth to account for just over 40% of total sales. The pharma unit saw sales decline a modest 4.7% to account for the remainder of the top line, as U.S. sales fell 5.7% and international decreased 1.6%.

Geographically, sales were strongest in Asia, rising 9.7% to account for 19.2% of sales. Sales fell 8.1% in the U.S. (46.2% of total sales), 10.5% in Europe (25.6%) and 4.5% everywhere else in the Western Hemisphere (9%). Product costs fell only 5.1% but management was able to reduce selling, general and administrative costs by 8%. However, $1.1 billion in recall and related expenses sent operating income down 14.4% to $2.2 billion. Net income fell 12% to $1.9 billion, or 70 cents per diluted share.

Year End Review and Outlook
Full-year sales fell 0.5% to $61.6 billion. The lack of a restructuring charge compared to last year helped push operating income ahead to $17 billion while net income rose 8.7% to $13.3 billion, or $4.78 per diluted share.

For the coming year, management said to expect earnings between $4.80 and $4.90 per share, though there again could be a number of "special items." At best, this would represent year-over-year growth of a couple of percent. Analysts project a similar level of full-year sales growth.

Bottom Line
At the current earnings valuation, shares of J&J are cheap at 12.4 times forward expectations. This represents one of the lowest multiples in the last 20 years, but it is warranted given the quality concerns and hits to the company's once solid image. Fortunately, none of the current issues appear to be serious and the company is still growing modestly. Overall though, a number of rivals, including Medtronic (NYSE:MDT), Teva Pharmaceutical (Nasdaq:TEVA), Roche (OTC:RHHBY), and Novartis (NYSE:NVS) trade at equally appealing valuations and have their acts together in terms of product manufacturing.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center